GlaxoSmithKline has an active research and development programme targeted at both seasonal and pandemic influenza and has recently committed over one billion pounds ($NZ2.96 billion) to expand capacity for manufacturing flu vaccine and its anti-viral influenza treatment Relenza® (zanamivir for inhalation).
http://www.scoop.co.nz/stories/SC0605/S00079.htm
Maybe this is why???
